Researchers are always looking for new ways to improve the effectiveness of antibody therapy – often by engineering cells to enhance certain immune mechanisms. One such promising mechanism is antibody-dependent cellular cytotoxicity (ADCC). In this article, Dr. Andy Racher explains how monoclonal antibodies designed to enhanced ADCC are primed for success and may usher in the next generation of antibody therapies.
You may also be interested in:
Out-Licensed Expression Technologies
Enhanced ADCC
Cell Line Development
Mammalian Expression Technologies
Read this article

View now
Latest content
Latest briefing from the Knowledge Center
Mammalian Biologics Drug Substance Manufacture MC1
Article
How Emerging Biotechs can Benefit by Partnering with a CDMO for Early Stage Development
The partnership between CDMOs and emerging biotech companies in early-stage development can be...
capsule image
White paper
Bridging the Gaps in Oral Dosage Research: 4 Focus Areas Highlighted by the UNGAP network
As our designated center of excellence for novel drug delivery systems, Innovaform™ Accelerator is...
Video
CAR-T Cells on the Fast Lane: From T-cell Selection to CAR-T Cell Drug Product in Just 3 Days
In this presentation, we explore the rapid growth of the CAR T market, driven by oncology...
Used as thumbnail for Powder to Particles podcast.
White paper
Unlocking the Potential of Carrier-Based Formulations: A Process Optimization Guide
Carrier-based formulations are commonly used in drug delivery systems, particularly in inhalation...
Webinar (on-demand)
Enhanced GS® CHO Vector Technology for Improved Expression Control of Biotherapeutic Proteins
Many of today’s expression platforms for recombinant protein production have been optimised for the...
Used as thumbnail for Powder to Particles podcast.
Video
Small Molecule API & HPAPI Development Capacity
This video presents Lonza's capabilities, facility locations, and timelines to assist biopharma...
Webinar (on-demand)
Linking Rational Design and Material-Sparing Strategies for Enabled Intermediates and Their Drug...
The rapid development of enabled forms and formulations is crucial for tackling the challenges posed...
CHI Colmar
Presentation (on-demand)
Pioneering Capsule Innovation: Accelerating Oral and Inhalable Drug Delivery
Watch Dr. Camille Dumont and Meeta Kratz's presentation at CPHI Worldwide 2024. Explore Lonza’s...
Innovaform
R&D Blog post
Transforming drug delivery through advanced capsule innovation
Capsules represent one of the oldest pharmaceutical dosage forms, with a history dating back to...
Biologics_Portsmouth_060
Article
Considerations for Successful Tech Transfer of a Biologics Upstream Process
Bioprocess experts from Lonza discuss in this European Pharmaceutical Review article how molecular...
Webinar (on-demand)
Excipients for Respiratory Delivery of Biologics
Local administration of biologic Active Pharmaceutical Ingredients to the lung via inhalation has...
Spray Drying - Bend
White paper
Optimizing Spray-Dried Dispersion Processes Through Risk-Based Development
This executive summary explores a risk-based approach to process qualification, demonstrating how...